A. Gregory Sorensen, M.D. was appointed as our Chief Strategy Officer in January 2026 and as a director in August 2023. Prior to serving as our Chief Strategy Officer, Dr. Sorensen served as our Chief Science Officer from August 2023 to January 2026. Dr. Sorensen has served as the Chief Executive Officer of our DeepHealth, Inc. ( DeepHealth ) subsidiary of the Company that is focused on using artificial intelligence and deep learning methods to advance medical care with a special emphasis on breast cancer imaging. The Company acquired DeepHealth in June 2020. Dr. Sorensen served as the President and Chief Executive Officer of Siemens Healthcare North America from 2011 to 2015. Prior to that, he served as a Professor at Harvard Medical School and as a neuroradiologist at Massachusetts General Hospital, where he worked from 1990 to 2011. Since 2021, Dr. Sorensen has been serving as a supervisory board member for Fresenius Medical Care AG (NYSE: FMS), a provider of products and services for people with chronic kidney failure. He also served as the Executive Chairman of the board of directors of IMRIS, Inc., which is focused on the integration of imaging technologies in a neurosurgical setting; a member of the board of directors for Lumina Pharmaceuticals, Inc.. Dr. Sorensen served as a Supervisory Board Member at Siemens Healthineers from 2018 to 2023. Dr. Sorensen holds a B.S. in biology from the California Institute of Technology, an M.S. in computer science from Brigham Young University, and an M.D. degree from Harvard Medical School. Dr. Sorensen brings broad-based expertise on the development and potential impact of new technologies, including artificial intelligence and machine learning, on imaging services and healthcare.